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Summary: Pancreatic phospholipase A2 and non-pancreatic ascitic phospholipases A2 were studied in sera of
healthy individuals and of patients suffering from sepsis or acute pancreatitis. In gel filtration experiments,
immunoreactive ascitic phospholipase A2, as determined in serum by a time-resolved fluoroimmunoassay,
eluted either unassociated with an apparent Mr of 10 000 — 14 000 or associated with proteins of high molecular
mass. Catalytically active ascitic phospholipase A2 was associated with high molecular weight proteins. In
acute pancreatitis the catalytically active and immunoreactive pancreatic phospholipase A2 eluted mainly as
a protein of Mr of 14000. The results of the gel filtration experiments indicate that pancreatic phospholipase
A2 is not associated with other proteins in human serum, whereas ascitic phospholipase A2 is associated with
protein(s) of relative high molecular weight, or exists in different polymeric forms. We also purified phospho-
lipase A2 from sera of healthy individuals by ion exchange chromatography and HPLC. The enzyme was
homogenous, displayed an Mr of approximately 13 500 as judged by SDS-polyacrylamide gel electrophoresis,
and reacted with an antibody raised against ascitic phospholipase A2.
Introduction „ . . . , ,. 1 1 1
merous cells and tissues including human tonsils, kid-
High concentrations of phospholipase A2*) catalytic ney, rheumatoid synovial cells, spleen and lung (8, 9).
activity have been found in sera of patients suffering The cytokines, interleukin-1 and tumour necrosis fac-
from a number of common and severe diseases, in- tor, increase the mRNA levels of group II phospho-
cluding septic shock (1), rheumatoid arthritis (2), lipase A2 and the secretion of the enzyme (10, 11).
acute pancreatitis (3), peritonitis (4) and multiple in- ^ , „ , , . „ « ,
/Cx c , « i, r A u u The mechanism of the elevation of extracellular groupmries (5). Secretory phospholipases A2 have been „ , , ,. 4 . . . . Λ «.
, -r A · + + *u u · r A-ff II phospholipase A2 activity in inflammatory diseasesclassified into two groups on the basis of differences . ,
 A . . , „ *
. , u . ,, ~ A. λ~Α u A ^ T U remains unclear. Activation may result from the mod-m their patterns of disulfide bonds. Group I phos- .„ . . , , /
, ,. Λ
 A . j. i r-, , ., r-,, ification of a modulator protein or membrane struc-phohpases A2 contain seven disulfide bridges. They ,.„ _ , . * . . . , t ,.
, j
 A . ,. . . . , . ture (12). The catalytic activity of phospholipase A2are abundant in mammalian pancreatic juices and in . _ . , . . .
 Λ
u , , ^ TT , , t. in sera or patients with acute pancreatitis is not alwayscobra and sea snake venoms. Group II phospholipases . . . .
 4 , . , . „
A . . . . . ΑΛ \ 4.1. Α· \ΓΑ pancreatic in origin. At least two immunologicallyA2 are non-pancreatic in origin and lack the disulfide ,. . , , ,? Α , , Λ *,*^
bridge between Cys 11 and 77 (6, 7). dlStmCt PhosPhohPases A> have been detected (13)'
^, r u u r A u i We recently purified a phospholipase A2 from theThe gene of a phospholipase A2 belonging to group .:r ^ r . /
TT u u t j j v X T A · * · ascitic fluid of patients suffering from ovanan carci-II has been cloned and its mRNA is present in nu- , . , . , ,
noma and peritoneal carcmosis, and developed an
immunoassay for its determination in body fluids,
i) Enzymes: including serum and plasma (14). The cellular source
Phospholipase A2, phosphatide 2-acylhydrolase (EC 3.1.1.4) of this enzyme is unknown. An antibody raised earlier
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against purified human pancreatic phospholipase A2
(15) does not react with the ascitic phospholipase A2
(14).
The purpose of the present work was to study the
ascitic and pancreatic-type phospholipases A2 in nor-
mal sera and in sera of patients suffering from acute
pancreatitis or sepsis. We found that there are two
pools of ascitic phospholipase A2 in serum: free and
protein-associated enzymes. In addition, we report
here the isolation of phospholipase A2 from human
serum as a nearly homogeneous protein as judged by
SDS-polyacrylamide gel electrophoresis.
Phospholipase A2 assays
The catalytic activity of phospholipase A2 was measured radio-
chemically by using either E. coli (strain K12) labelled with
[14C]oleic acid (16) or a mixture of unlabelled dipalmitoyl-
phosphatidylcholine (Sigma, St. Louis, MO, USA) and [2-
3H]dipalmitoyl-phosphatidylcholine (NEN, Boston, MA, USA)
as substrate (17, 18). The enzyme proteins were measured im-
munochemically by time-resolved fluoroimmunoassays with
antisera raised in rabbits against
1) the phospholipase A2 purified from the ascitic fluid of pa-
tients with ovarian carcinoma and peritoneal carcinosis (ascitic
fluid phospholipase A2), and
2) the secretory pancreatic phospholipase A2 purified from
human pancreatic tissue (pancreatic phospholipase A2), as de-
scribed elsewhere (14, 19, for ascitic and pancreatic phospho-
lipase A2, respectively).
Materials and Methods
Patients
Normal sera were obtained from three healthy laboratory work-
ers. The sepsis sera were from hospitalized patients from the
University Hospital of Ulm (Germany). Sera of a patients
suffering from acute pancreatitis were from the University
Central Hospital of Turku (Finland). Sera were stored at
-20°C until used.
Protein de te rmina t ion
Protein was determined according to the method of Lowry et
al. (20).
Statistical analysis
Student's t-test was used for the statistical analysis.
Chromatography
Gel filtration chromatography of serum was performed on a
1.6 χ 40 cm Sephadex G75 (Pharmacia, Uppsala, Sweden)
column equilibrated with 20 mmol/1 Tris-HCl (pH 8) buffer
containing 0.15 mol/1 NaCl. The column was eluted at a flow
rate of 24 ml/h. The volumes of the chromatographed sera were
1-2 ml.
Phospholipase A2 was purified from serum by ion exchange
chromatography on a 1.6 χ 10cm CM-Sepharose CL6B (Phar-
macia, Uppsala, Sweden) column equilibrated and washed free
of anionic proteins with 2.5 mmol/1 Tris-HCl (pH 7.5) contain-
ing 0.15 mol/1 NaCl. The column was eluted stepwise with
buffered 0.5 mol/1 and 1.5 mol/1 NaCl.
The phospholipase A2-rich pool from ion exchange or gel fil-
tration chromatography was applied to a reverse-phase C8-
column (Aquapore Octyl RP 300, 0.46 χ 22 cm, Brownlee
Lab., Santa Clara, CA, USA) for HPLC. The column was
equilibrated, and after application of the sample, washed free
of unbound proteins with 1 ml/1 trifluoroacetic acid. Phospho-
lipase A2 was eluted by using an acetonitrile gradient (95%
acetonitrile/1 ml/1 trifluoroacetic acid from 0 to 15% during 5
minutes and thereafter from 15 to 50% during 90 minutes.
Electrophoresis and immunoblot t ing
SDS-polyacrylamide gel electrophoresis was performed with
the PhastSystem of Pharmacia (Uppsala, Sweden) using
PhastGel gradient polyacrylamide gels (8 - 25%). Protein bands
were visualized with Coomassie blue staining. Proteins were
transferred to nitrocellulose filters with the PhastSystem semi-
dry immunoblotting device as described by the manufacturer.
Nitrocellulose filters were immunostained by using a Vectastain
ABC-kit (Vector Laboratories Inc., Burlingame, CA, USA).
Phospholipase A2 purified from normal serum was detected
with affinity-purified anti-ascitic phospholipase A2 antiserum
(7 mg/1). The phospholipase A2 binding component was inden-
tified using rabbit antiserum to human albumin (Dako, Glos-
trup, Denmark).
Results
Characterization of two phospholipases A2 in
serum in sepsis and acute pancreatitis
In gel filtration chromatography, immunoreactive as-
citic phospholipase A2 eluted in two peaks, one as-
sociated with high molecular mass proteins, and the
other unassociated with an apparent Mr of 10000 —
14000 in normal serum and in sera of patients with
sepsis and acute pancreatitis. Catalytically active
phospholipase A2 eluted mainly in association with
high molecular-weight proteins in normal serum and
in serum from a septic patients (fig. 1 a, b). In the
serum of a patient with acute pancreatitis, the im-
munoreactivity and catalytic activity of pancreatic
phospholipase A2 eluted mainly as a protein of Μτ
about 14000 (fig. 1 c). The catalytic activity and the
content of pancreatic and ascitic phospholipase A2 in
the sera used in the gel filtration studies are presented
in table 1. Table 2 gives the elution of the catalytic
activity and immunoreactivity of pancreatic and as-
citic phospholipase A2 in the sera chromatographed
on Sephadex G75.
The concentration of ascitic phospholipase A2 was
within the reference interval in patients suffering from
sepsis (p = 0.464) or acute pancreatitis (p = 0.6590)
(tab. 3). The concentration of pancreatic phospholi-
pase A2 was elevated in pancreatitis (p = 0.0022) but
not in sepsis (p = 0.1083). The catalytic activity was
clearly higher than normal in sepsis and pancreatitis
(p = 0.000 and p = 0.002, respectively).
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Fig. 1. Gel filtration chromatography of serum phospholipase
A2.Elution of normal serum (a), sepsis serum (b), and
pancreatitis serum (c) from a Sephadex G75 column.
Phospholipase A2 immunoreactivity (·, ascitic phos-
pholipase A2; ·, pancreatic phospholipase A2) was
measured by time resolved fluoroimmunoassay and
phospholipase A2 catalytic activity (o) by using 14C-
labelled E. coli as substrate in the collected fractions as
described under "Materials and Methods". Absorbance
was measured at 280 nm (D). Elution of bovine serum
albumin (Mr = 67000) and chymotrypsinogen
(Mr = 25 000) used as molecular mass markers is indi-
cated by arrows.
Macromolecular phospholipase A2 in serum
The fractions containing phospholipase A2 associated
with high molecular weight proteins after gel filtration
chromatography were pooled and applied to a reverse
phase column for HPLC. Phospholipase A2 eluted at
approximately 30 per cent of acetonitrile (14). After
chromatography, phospholipase A2-active fractions
were incubated with NaSCN, and phospholipase A2
was separated from the main protein peak by Seph-
adex G75 gel filtration chromatography (fig. 2). As a
control experiment, phospholipase A2-containing
fractions obtained from reversed phase chromatog-
raphy were chromatographed without NaSCN treat-
ment on a Sephadex G75 column. Phospholipase A2
eluted in the fraction of high molecular weight pro-
teins (data not shown).
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Fig. 2. Macromolecular phospholipase A2 in serum.
Phospholipase A2-containing fractions from reverse
phase chromatography on HPLC were pooled and in-
cubated with 3.5 mol/1 NaSCN in 50 mmol/1 phosphate-
buffered 0.15 mol/1 NaCl (pH 7.3) for 10 minutes at
room temperature. Phospholipase A2 was separated
from the main protein peak by Sephadex G75 as de-
scribed in the section "Materials and Methods". Ab-
sorbance at 280 nm (A) and immunoreactivity of ascitic
phospholipase A2 (·) were measured. The main protein
peak eluted in fractions 15—20 and ascitic phospholi-
pase A2 in fractions 28 — 34.
Tab. 1. Sera used in gel filtration chromatography.
Serum
Normal
Sepsis; male, 73a
Pancreatitis;
male, 39a
Ascitic
phospho-
lipase A2
mg/1
107.2
104.5
138.4
Pancreatic
phospho-
lipase A2
μ§/1
5.0
5.1
61.4
Phospho-
lipase A2
U/l
2.2
12.7
5.2
SDS-polyacrylamide gel electrophoresis of the main
peak (possibly a phospholipase A2 binding protein)
gave a single band of Mr approximately 67 000. Im-
munoblotting of this protein with the anti-albumin
antibody gave a single band (fig. 3). The antibody
against ascitic phospholipase A2 did not recognize this
protein as determined by time resolved fluoroimm -
noassay (fig. 2).
Purif icat ion of phospholipase A2 from nor-
mal serum
In ion exchange chromatography of normal serum,
immunoreactive ascitic phospholipase A2 was eluted
in two discrete peaks and phospholipase A2 catalytic
activity in one peak by 1.5 mol/1 NaCl (fig. 4). Only
traces of immunoreactive ascitic phospholipase A2
were eluted by 0.5 mol/1 NaCl. The catalytically active
phospholipase A2 was found to represent only about
5 per cent of the total phospholipase A2 in serum.
The major fraction of phospholipase A2 immuno-
reactivity (nearly 95 per cent of the total phospholi-
pase A2 in serum, fig. 4), which was contained in this
peak, was further purified by HPLC. From the ap-
plication of 20 ml of serum (1200 mg of protein) to
the ion exchange column, the procedure yielded 0.490
mg of ascitic phospholipase A2, devoid of catalytic
activity. The apparent MT of the purified serum-phos-
pholipase A2 was approximately 13 500 in SDS-poly-
acrylamide gel electrophoresis. The antibody against
ascitic phospholipase A2 recognized the purified phos-
pholipase A2 in immunoblotting (fig. 3).
Tab. 2. Summary of the results of gel filtration chromatography.
Serum Relative molecular mass Ascitic phospholipase
of phospholipase A2 A2
immunoreactivity
Pancreatic phospholipase Phospholipase
A2 A2
immunoreactivity catalytic activity
Normal
Sepsis
Pancreatitis
10000-14000 + - -
67000 + - +
10000-14000 +
67000 + - +
10000-14000 + + +
67000 + - +
Tab. 3. Catalytic activity concentration of phospholipase A2 and mass concentration of ascitic phospholipase A2 and pancreatic
phospholipase A2 in serum in acute pancreatitis (20 consecutive samples from seven patients) and sepsis (24 consecutive
samples from four patients). Normal values were obtained from 20 healthy blood donors for catalytic activity of
phospholipase A2 and pancreatic phospholipase A2 and from 20 healthy laboratory workers for ascitic phospholipase A2.
Student's t-test was used for statistical analysis.
Patients Catalytic concentration
of phospholipase A2
Ascitic phospholipase
A2
Pancreatic phospholipase
A2
(U/l) (mg/1)
Sepsis
Pancreatitis
Normal
24
20
20
13.7 (SD8.7)
16.8 (SD 18.6)
2.1 (SD0.8)
ρ = 0.0000
ρ = 0.0023
77.4 (SD 57.1)
72.3 (SD 37.8)
67.8 (SD 23. 5)
p = 0.4604
p = 0.6590
10.4 (SD 13.8)
26.3 (SD 26.3)
5.5 (SD 1.2)
p = 0.1083
p = 0.0022
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Fig. 3. SDS-polyacrylamide gel electrophoresis (a) and immu-
noblotting (b) of phospholipase A2 and phospholipase
A2 binding component in serum,
a: Lane 1, molecular mass standards (Mr 14400 —
94000); lane 2, senim (1 : 40); lane 3, phospholipase A2
purified from normal serum; lane 4, phospholipase A2
binding component.
b: Detection of ascitic phospholipase A2 and phospho-
lipase A2 binding component by immunoblotting as
described in the section "Materials and Methods".
Lane 1, molecular mass standards stained with amido-
black (MT = 14400-94000);
lane 2, phospholipase A2 purified from normal serum;
lane 3, phospholipase A2 binding component. Phospho-
lipase A2 was detected with the polyclonal rabbit an-
tiascitic phospholipase A2 antibody and phospholipase
A2 binding component with polyclonal rabbit antial-
bumin antibody.
Discussion
Two phospholipases A2 (ascitic and pancreatic phos-
pholipase A2) were characterized in normal serum and
in sera of patients suffering from sepsis or acute
pancreatitis. In gel filtration chromatography on
Sephadex G75, ascitic phospholipase A2 eluted with
proteins of high (Mr 67000) and low (Afr 10000-
14000) molecular mass as measured with time re-
solved fluoroimmunoassay. Pancreatic secretory
phospholipase A2 eluted as a protein of Afr about
14 000. Vadas (1) reported that phospholipase A2 from
plasma in septic shock had an Mr of approximately
14000 in gel filtration chromatography on Sephadex
G75. In the present study, we purified from normal
serum a phospholipase A2 that reacted with the an-
tibody raised against ascitic fluid phospholipase A2
but was devoid of catalytic activity. This enzyme
protein had an Mr of approximately 13 500. However,
in our gel filtration experiments, the catalytic activity
of phospholipase A2 eluted mainly in association with
high molecular weight protein(s), and only insignifi-
cant activity was found in the fractions containing
proteins of low molecular mass.
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Fig. 4. Ion exchange chromatography of phospholipase A2 in
normal serum.
Serum was applied to a CM-Sepharose CL6B column.
Phospholipase A2 catalytic activity (o) was measured
by using 14C-labelled E. coli as substrate and immuno-
reactivity (·, phospholipase A2) by time resolved fluo-
roimmunoassay as described under "Materials and
Methods". Absorbance was measured at 280 nm (D).
Fractions 25 — 33 (peak I) and 41—42 (peak II) were
pooled. Each fraction contained 1.5 ml.
The concentration of ascitic phospholipase A2 in sera
of patients suffering from acute pancreatitis were
within the reference interval, but extremely high com-
pared with the concentration of pancreatic phospho-
lipase A2 in the same serum samples. The possibility
that the anti-ascitic-phospholipase A2 antibody rec-
ognizes some non-phospholipase A2 material cannot
be excluded unequivocally by the methods used. How-
ever, we have excluded cross reactions with human
albumin, human IgG, collagen type III and collagen
type IV in the immunoassay for ascitic phospholipase
A2 (results not shown).
Cellular calcium-dependent phospholipases A2 may
be classified into at least two groups according to
distinct characteristics of their primary structure (6).
In addition to the pancreas, pancreatic-type phospho-
lipase A2 (group I) is present in cobra venom, spleen
and lung (21 — 23). Phospholipases A2 from platelet
(24), spleen (25), liver (26) and ascitic fluid (27, 28)
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resemble the phospholipases A2 found in crotalic
snake venoms in their primary structure and are class-
ified in group II. Antibodies against group I phos-
pholipases A2 do not cross-react with group II phos-
pholipases A2 (29, 26, 30). Our results show that
human ascitic phospholipase A2 and pancreatic phos-
pholipase A2 are immunologically distinct proteins.
The present gel filtration studies indicate that ascitic
phospholipase A2 is partly associated with high mo-
lecular weight protein(s) in serum. Incubation of the
phospholipase A2-containing high molecular weight
peak with NaSCN dissociates phospholipase A2 from
other proteins. Characterization of this protein by
SDS-PAGE revealed one band of MT approximately
67000. Additionally, the anti-albumin antibody rec-
ognized this protein in immunoblotting. It was re-
ported earlier that phospholipase A2 binds to albumin
(31). Binding to other proteins such as lipoproteins
cannot be excluded.
Ascitic phospholipase A2 may also exist in different
polymeric forms in serum (32, 33). Rat lung contains,
in addition to a high molecular weight phospholipase
A2, two minor fractions with phospholipase A2 activ-
ity: a monomer (Mr 12000) and a dimer (Mr 25000)
(34). An antiserum raised against Naja naja venom
phospholipase A2 cross-reacted with 30000 and
45 000 proteins from guinea pig alveolar macrophages
and rat lymphocytes, and displayed a weak activity
toward a Mr 14000 protein (35). Similarly, an anti-
body against denatured rat platelet phospholipase A2
detected three protein bands of Mr about 14000,
32000 and 44000 in rat platelet lysate (36). In addi-
tion to low molecular mass phospholipases A2 (37),
enzymes of high molecular mass have been found in
monocytic leukaemia cells (38, 39), rat serum (40),
rat renal mesangial cells (41) and rat lung (34).
The results of the present gel filtration and immu-
noblotting experiments indicate that the ascitic phos-
pholipase A2 may either be associated with a protein
of higher molecular weight, or exists in different po-
lymeric forms in serum. Polymerization or protein
association may change the catalytic properties of the
enzyme.
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